Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Nerl

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Klinische Wochenschrift|April 15, 1987
Dose-response relationship in the treatment of idiopathic thrombocytopenic purpura with intravenous immunoglobulinB Emmerich, E Hiller, F Woitinas, et al.
British Journal of Haematology|July 1, 1994
Peripheral T-cell non-Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T-zone lymphoma. The Kiel Lymphoma Study GroupW Siegert, C Nerl, M Engelhard, et al.
European Journal of Haematology|September 30, 2005
Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression--report of two casesM Starck, F Abedinpour, U Dendorfer, et al.
Deutsche Medizinische Wochenschrift (1946)|July 26, 1991
[HIV-associated lymphomas]C Scheidegger, B Heinrich, M Popescu, et al.
Scandinavian Journal of Immunology|February 1, 1993
Leukaemic T cells from patients with chronic lymphocytic leukaemia of T-cell origin respond to Staphylococcus aureus enterotoxin superantigensR Metzger, G Melmer, S Schondelmaier, et al.
Acta Medica Austriaca|January 1, 1985
[Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon]W Aulitzky, G Gastl, J Troppmair, et al.
British Journal of Haematology|March 1, 1996
Regulated plasma levels of colony-stimulating factors, interleukin-6 and interleukin-10 in patients with acute leukaemia and non-hodgkin's lymphoma undergoing cytoreductive chemotherapyG Reisbach, T Kamp, G Welzl, et al.
Nanomedicine (London, England)|July 29, 2011
Imaging methods for determining uptake and toxicity of carbon nanotubes in vitro and in vivoHannah C Nerl, Crystal Cheng, Angela E Goode, et al.
Blood|June 1, 1997
Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemiaW U Knauf, B Ehlers, B Mohr, et al.
Leukemia|June 1, 1989
Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patientsG Gastl, M Werter, B De Pauw, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Klinische Wochenschrift|April 15, 1987
Dose-response relationship in the treatment of idiopathic thrombocytopenic purpura with intravenous immunoglobulinB Emmerich, E Hiller, F Woitinas, et al.
British Journal of Haematology|July 1, 1994
Peripheral T-cell non-Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T-zone lymphoma. The Kiel Lymphoma Study GroupW Siegert, C Nerl, M Engelhard, et al.
European Journal of Haematology|September 30, 2005
Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression--report of two casesM Starck, F Abedinpour, U Dendorfer, et al.
Deutsche Medizinische Wochenschrift (1946)|July 26, 1991
[HIV-associated lymphomas]C Scheidegger, B Heinrich, M Popescu, et al.
Scandinavian Journal of Immunology|February 1, 1993
Leukaemic T cells from patients with chronic lymphocytic leukaemia of T-cell origin respond to Staphylococcus aureus enterotoxin superantigensR Metzger, G Melmer, S Schondelmaier, et al.
Acta Medica Austriaca|January 1, 1985
[Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon]W Aulitzky, G Gastl, J Troppmair, et al.
British Journal of Haematology|March 1, 1996
Regulated plasma levels of colony-stimulating factors, interleukin-6 and interleukin-10 in patients with acute leukaemia and non-hodgkin's lymphoma undergoing cytoreductive chemotherapyG Reisbach, T Kamp, G Welzl, et al.
Nanomedicine (London, England)|July 29, 2011
Imaging methods for determining uptake and toxicity of carbon nanotubes in vitro and in vivoHannah C Nerl, Crystal Cheng, Angela E Goode, et al.
Blood|June 1, 1997
Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemiaW U Knauf, B Ehlers, B Mohr, et al.
Leukemia|June 1, 1989
Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patientsG Gastl, M Werter, B De Pauw, et al.
Pageof 8